Centessa Pharmaceuticals plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Company was acquired and is no longer a public stock to trade, affecting all shareholders' ownership.
Major company decision requires shareholder approval before the deal can close and change ownership.
Major event signals company restructuring or sale, which could change your investment significantly.
Shows company earnings and financial health for early 2026, helping you understand business performance.
Annual report reveals company profits, losses, and financial position for the entire 2025 year.
Major deal announcement shows company direction changing and needs shareholder approval before closing.
Leadership changes affect company management and strategy decisions going forward.
Stocky reads Centessa Pharmaceuticals plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Centessa Pharmaceuticals plc's most recent tracked filing was a 8-K on 24 Jun 2026: Acquisition completed, Nasdaq delisting effective June 23, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.